CC-93269 for Multiple Myeloma

Phase-Based Progress Estimates
Multiple MyelomaCC-93269 - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new drug for people with multiple myeloma that has come back or does not respond to treatment.

Eligible Conditions
  • Multiple Myeloma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

4 Primary · 16 Secondary · Reporting Duration: Up to 60 months

Up to 48 months
Pharmacokinetics - accumulation index of CC-93269
Up to 60 months
Adverse Events (AEs)
Dose Limiting Toxicity (DLT)
Duration of Response
Evaluate measures of tumor sensitivity/ resistance to CC-93269
Maximum Tolerated Dose (MTD)
Non-Tolerated Dose (NTD)
Overall Response Rate (ORR)
Overall Survival
Pharmacokinetics - AUC
Pharmacokinetics - CL
Pharmacokinetics - Cmax
Pharmacokinetics - Cmin
Pharmacokinetics - Vss
Pharmacokinetics - accumulation index of alnuctamab
Pharmacokinetics - t1/2
Pharmacokinetics - tmax
Presence and frequency of anti-drug antibodies (ADA)
Progression Free Survival
Time to Response

Trial Safety

Trial Design

1 Treatment Group

Administration of CC-93269
1 of 1

Experimental Treatment

220 Total Participants · 1 Treatment Group

Primary Treatment: CC-93269 · No Placebo Group · Phase 1

Administration of CC-93269
Experimental Group · 1 Intervention: CC-93269 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 60 months

Who is running the clinical trial?

CelgeneLead Sponsor
625 Previous Clinical Trials
172,950 Total Patients Enrolled
139 Trials studying Multiple Myeloma
39,100 Patients Enrolled for Multiple Myeloma
Michael R Burgess, MD, PhDStudy DirectorCelgene
Bristol-Myers SquibbStudy DirectorBristol-Myers Squibb
1,407 Previous Clinical Trials
3,308,947 Total Patients Enrolled
62 Trials studying Multiple Myeloma
21,513 Patients Enrolled for Multiple Myeloma

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: